Skip to main content
. 2019 Sep;19(9):973–987. doi: 10.1016/S1473-3099(19)30156-2

Table 2.

Serious adverse events

IPT (n=681 women, n=524 infants)*
IST (n=854 women, n=712 infants)
SST (n=744 women, n=634 infants)
Number of participants with event (%) Total number of events Incidence per 100 person-years (95% CI) Number of participants with event (%) Total number of events Incidence per 100 person-years (95% CI) Number of participants with event (%) Total number of events Incidence per 100 person-years (95% CI)
Mothers
Any serious adverse event 56 (8·2%) 85 54·2 (43·3–67·1) 77 (9·0%) 105 47·2 (38·6–57·2) 71 (9·5%) 113 60·4 (49·8–72·6)
Pregnancy, puerperium and perinatal conditions 47 (6·9%) 62 39·6 (30·3–50·7) 60 (7·0%) 71 31·9 (25–40·3) 51 (6·9%) 65 34·7 (26·8–44·3)
Infections and infestations 8 (1·2%) 8 5·1 (2·2–10·1) 9 (1·1%) 11 4·9 (2·5–8·9) 17 (2·3%) 26 13·9 (9·1–20·4)
Gastrointestinal disorders 2 (0·3%) 3 1·9 (0·4–5·6) 1 (0·1%) 2 0·9 (0·1–3·3) 2 (0·3%) 3 1·6 (0·3–4·7)
Surgical and medical procedures 0 0 0 (0–0) 1 (0·1%) 1 0·4 (0–2·5) 1 (0·1%) 1 0·5 (0–3)
Blood and lymphatic system disorders 7 (1·0%) 7 4·5 (1·8–9·2) 12 (1·4%) 14 6·3 (3·4–10·6) 15 (2·0%) 15 8 (4·5–13·2)
Nervous system disorders 0 0 0 (0–0) 0 0 0 (0–0) 1 (0·1%) 2 1·1 (0·1–3·9)
Reproductive system and breast disorders 1 (0·1%) 1 0·6 (0–3·6) 1 (0·1%) 1 0·4 (0–2·5) 0 0 0 (0–0)
Injury, poisoning and procedural complications 0 0 0 (0–0) 1 (0·1%) 1 0·4 (0–2·5) 0 0 0 (0–0)
Respiratory, thoracic and mediastinal disorders 1 (0·1%) 1 0·6 (0–3·6) 0 0 0 (0–0) 0 0 0 (0–0)
Vascular disorders 1 (0·1%) 1 0·6 (0–3·6) 0 0 0 (0–0) 0 0 0 (0–0)
Metabolism and nutrition disorders 1 (0·1%) 1 0·6 (0–3·6) 2 (0·2%) 2 0·9 (0·1–3·3) 0 0 0 (0–0)
Hepatobiliary disorders 0 0 0 (0–0) 1 (0·1%) 1 0·4 (0–2·5) 0 0 0 (0–0)
Cardiac disorders 0 0 0 (0–0) 1 (0·1%) 1 0·4 (0–2·5) 1 (0·1%) 1 0·5 (0–3)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 1 (0·1%) 1 0·6 (0–3·6) 0 0 0 (0–0) 0 0 0 (0–0)
Infants
Any serious adverse event 40 (7·6%) 56 88 (66·5–114·3) 53 (7·4%) 75 89·5 (70·4–112·2) 51 (8·0%) 69 86·5 (67·3–109·5)
Congenital, familial and genetic disorders 11 (2·1%) 11 17·3 (8·6–30·9) 18 (2·5%) 19 22·7 (13·7–35·4) 19 (3·0%) 19 23·8 (14·3–37·2)
Pregnancy, puerperium and perinatal conditions 6 (1·1%) 6 9·4 (3·5–20·5) 14 (2·0%) 14 16·7 (9·1–28) 10 (1·6%) 12 15 (7·8–26·3)
Infections and infestations 18 (3·4%) 19 29·9 (18–46·6) 23 (3·2%) 23 27·5 (17·4–41·2) 24 (3·8%) 25 31·4 (20·3–46·3)
Gastrointestinal disorders 0 0 0 (0–0) 1 (0·1%) 1 1·2 (0–6·7) 2 (0·3%) 2 2·5 (0·3–9·1)
Surgical and medical procedures 0 0 0 (0–0) 1 (0·1%) 1 0 (0–0) 0 0 0 (0–0)
Blood and lymphatic system disorders 1 (0·2%) 1 1·6 (0–8·8) 2 (0·3%) 2 2·4 (0·3–8·6) 0 0 0 (0–0)
Nervous system disorders 1 (0·2%) 1 1·6 (0–8·8) 1 (0·1%) 1 1·2 (0–6·7) 0 0 0 (0–0)
Reproductive system and breast disorders 1 (0·2%) 1 1·6 (0–8·8) 0 0 0 (0–0) 0 0 0 (0–0)
Respiratory, thoracic, and mediastinal disorders 13 (2·5%) 13 20·4 (10·9–34·9) 9 (1·3%) 9 10·7 (4·9–20·4) 10 (1·6%) 10 12·5 (6–23·1)
Metabolism and nutrition disorders 0 0 0 (0–0) 3 (0·4%) 3 3·6 (0·7–10·5) 0 0 0 (0–0)
Hepatobiliary disorders 0 0 0 (0–0) 0 0 0 (0–0) 1 (0·2%) 1 1·3 (0–7)
General disorders and administration site conditions 2 (0·4%) 3 4·7 (1–13·8) 2 (0·3%) 2 2·4 (0·3–8·6) 0 0 0 (0–0)
Neoplasms benign, malignant, and unspecified (including cysts and polyps) 1 (0·2%) 1 1·6 (0–8·8) 0 0 0 (0–0) 0 (0·0%) 0 0 (0–0)

All SAEs were coded using the Medical Dictionary of Regulatory Affairs and are presented here according to their system organ class, the highest level in the dictionary. IPT=intermittent preventive treatment. IST=intermittent screening and treatment. SST=single screening and treatment.

§ Excluding twin births, including liveborn and stillborn infants.

*

Total follow-up was 222·2 years in women and 83·8 years in infants.

Total follow-up was 156·6 years in women and 63·6 years in infants.

Total follow-up was 187·1 years in women and 79·7 years in infants.